DNA Immune Response Targeted Protein Degradation Vaccine 
Drug Discovery World
MAY 30, 2023
Very recent data from Moderna’s and BioNTech’s personalised vaccines in combination with ICIs in melanoma and pancreatic cancer respectively have shown dramatic improvements when given as part of a triple combination (vaccine plus ICI and chemo/radiotherapy).
Drug Target Review
OCTOBER 4, 2023
2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. Florian S, Mitchison TJ. Chang, P. &
Expert insights. Personalized for you.
130 
Let's personalize your content